Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04122833
Other study ID # ML41560
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date September 30, 2019
Est. completion date December 31, 2024

Study information

Verified date August 2022
Source Konkuk University Medical Center
Contact In Ae Kim, MD. Ph.D
Phone 01035438353
Email 20180618@kuh.ac.kr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The concomitant co-mutation with epidermal growth factor receptor (EGFR) mutation might influence the clinical outcomes. The investigators will identify the impact of concommitant mutation on clinical outcome in patients with advanced -EGFR mutated adenocarcinoma. The investigators will compare the genetic alterations between tumors of pre and post Tyrosin Kinase Inhibitor(TKI) treatments and predict the resistance mechanism for EGFR-TKIs by next-generation sequencing(NGS) analysis.


Description:

The current standard therapies in the treatment of advanced EGFR-mutated lung cancer patients are the 1st or 2nd EGFR-TKIs. Although 70-80% of patients treated by EGFR-TKIS show good responses, they have progression after around 12 months. The concomitant co-mutation with EGFR mutation might influence the drug response of EGFR TKI. The investigators will compare the progression-free survival (PFS) of EGFR-TKI according to co-occuring mutations. The patients experience the change of molecular profiles after using the TKI. Therefore, the investigators will investigate the molecular profiles through NGS panel with foundation medicine in the tissue of pre/post EGFR-TKI, compare the change of the molecular profiles and tumor mutation burden(TMB), and identify novel mechanisms of drug resistance. The investigators will collect the tumor tissues and blood of around 80 patients in multi-centers prospectively. Then, They will be sent to FoundationOne in the US and perform NGS analysis. The type of EGFR-TKIs would be selected according to physicians' preference. NGS will be performed twice before the EGFR-TKIs treatment and after the progression.


Recruitment information / eligibility

Status Recruiting
Enrollment 80
Est. completion date December 31, 2024
Est. primary completion date September 30, 2023
Accepts healthy volunteers
Gender All
Age group 19 Years and older
Eligibility Inclusion Criteria: 1. Signed Informed Consent Form 2. Age =19 years 3. EGFR-mutated stage IV lung adenocarcinoma patients 4. Archival biopsy tissues which are from core needle biopsies, endobronchial ultrasound (EBUS) guided- lymph node biopsy or lymph node excisional biopsy at baseline and at radiologic progression 5. Availability of the 10 unstained slides and 1 H&E slides at pre/ post TKI treatment 6. Samples should contain a minimum of 20% viable tumor cells that preserve Exclusion Criteria: Tumor tissue from bone metastases that have been decalcified are not acceptable. -

Study Design


Intervention

Other:
Next generation sequencing
observational study

Locations

Country Name City State
Korea, Republic of Asan medical center Seoul
Korea, Republic of Catholic university medical center, Seoul St. Mary's Hospital Seoul

Sponsors (3)

Lead Sponsor Collaborator
Konkuk University Medical Center Foundation Medicine, Roche Diagnostics

Country where clinical trial is conducted

Korea, Republic of, 

References & Publications (5)

Kim Y, Lee B, Shim JH, Lee SH, Park WY, Choi YL, Sun JM, Ahn JS, Ahn MJ, Park K. Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC. J Thorac Oncol. 2019 Feb;14(2):193-202. doi: 10.1016/j.jtho.2018.10.150. Epub 2018 Nov 1. — View Citation

Offin M, Rizvi H, Tenet M, Ni A, Sanchez-Vega F, Li BT, Drilon A, Kris MG, Rudin CM, Schultz N, Arcila ME, Ladanyi M, Riely GJ, Yu H, Hellmann MD. Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers. Clin Cancer Res. 2019 Feb 1;25(3):1063-1069. doi: 10.1158/1078-0432.CCR-18-1102. Epub 2018 Jul 25. — View Citation

Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, Su WC, Bennouna J, Kato T, Gorbunova V, Lee KH, Shah R, Massey D, Zazulina V, Shahidi M, Schuler M. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013 Sep 20;31(27):3327-34. doi: 10.1200/JCO.2012.44.2806. Epub 2013 Jul 1. — View Citation

Socinski MA, Villaruz LC, Ross J. Understanding Mechanisms of Resistance in the Epithelial Growth Factor Receptor in Non-Small Cell Lung Cancer and the Role of Biopsy at Progression. Oncologist. 2017 Jan;22(1):3-11. doi: 10.1634/theoncologist.2016-0285. Epub 2016 Nov 7. — View Citation

Yu HA, Suzawa K, Jordan E, Zehir A, Ni A, Kim R, Kris MG, Hellmann MD, Li BT, Somwar R, Solit DB, Berger MF, Arcila M, Riely GJ, Ladanyi M. Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance. Clin Cancer Res. 2018 Jul 1;24(13):3108-3118. doi: 10.1158/1078-0432.CCR-17-2961. Epub 2018 Mar 12. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change of mutation profiles between pre/post TKI treatment Comparison of the kinds of the mutation between pre- and post TKI treatment through study completion, an average of 1 year
Secondary PFS according to the co-occurring mutations with pre-TKI treatment The investigators will compared the PFS according to the kinds of co-occuring genetic alteration in patient with EGFR -mutated adenocarcinoma before the EGFR TKI treatment through study completion, an average of 1 year
Secondary The number and the kinds of co-occurring mutations on tumors before and after TKI treatment The investigators will collect the information about the number and the kinds of co-occurring mutations on tumors before and after TKI treatment in Foundation medicine NGS through study completion, an average of 1 year
Secondary The correlation between the change of variant allele frequency(VAF) and drug response in matched tumors tissues before and after TKI treatment The investigators will analyze the correlation with the change of the VAF and PFS in matched tumors tissues before and after TKI treatment through study completion, an average of 1 year
Secondary Tumor mutation burden in tumors tissues before and after TKI treatment The investigators will compare the TMB in tumors tissues before and after TKI through study completion, an average of 1 year
Secondary The concordance the the mutation profiles in the NGS results of tissue and blood in the same patients The investigators will compare the concordance of the mutation profile in tumors and blood before TKI treatment through study completion, an average of 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT04557449 - Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors Phase 1/Phase 2
Terminated NCT04027946 - LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Phase 2
Not yet recruiting NCT05079022 - ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas Phase 1/Phase 2
Completed NCT02616211 - An Integrated Approach to Treating Recurrent Thoracic Carcinomas Resistant to Tyrosine Kinase Inhibitors
Completed NCT03184571 - Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC Phase 2
Recruiting NCT05550961 - APOLLO 11, Consortium of Italian Centers Involved in Treatment of Patients With Lung Cancer Treated With Innovative Therapies: Real World Data and Translational Reaserch
Active, not recruiting NCT05292859 - Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs
Not yet recruiting NCT05565677 - Prognostic Value of Lung Cancer MicroAnatomy in 3D
Completed NCT05252676 - Evaluation of Correlations Between Radiologic Features and Pathologic Subtypes of GGO LUAD Via WMS (ECTOP-1011)
Recruiting NCT03838588 - The Tracking Molecular Evolution for NSCLC (T-MENC) Study
Recruiting NCT04105270 - RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial Phase 2
Not yet recruiting NCT02946216 - ALK/ROS1/MET Mutations on Plasma ctDNA in Patients With NSCLC N/A
Completed NCT00073398 - Vaccine Treatment for Advanced Non-Small Cell Lung Cancer Phase 1/Phase 2
Recruiting NCT04770688 - Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib Phase 1/Phase 2
Completed NCT04165759 - HRCT in Prediction of Tumor Invasion in GGO Lung Adenocarcinoma (ECTOP-1008)
Completed NCT04086680 - The Detection of EGFR Mutations in Liquid Based Cytology Samples
Completed NCT01362790 - SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma Phase 1/Phase 2
Recruiting NCT06299163 - NM32-2668 in Adult Patients With Selected Advanced Solid Tumors Phase 1
Recruiting NCT03298763 - Targeted Stem Cells Expressing TRAIL as a Therapy for Lung Cancer Phase 1/Phase 2
Recruiting NCT02804646 - Endostar Durative Transfusion Combined With Chemotherapy in the Treatment of Advanced Lung Adenocarcinoma Phase 4